TVTX vs BLTE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TVTX · Travere Therapeutic$47.00 ▼ 2.69%
BLTE · Belite Bio$127.38 ▼ 15.65%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TVTX +31.3%
- BLTE -6.3%
Head to head
| Metric | TVTX | BLTE |
|---|---|---|
| Price | $47.00 | $127.38 |
| Change today | ▼ 2.69% | ▼ 15.65% |
| Market cap | $4.51B | $5.17B |
| Return, 3 months | -27.9% | -19.8% |
| Return, year to date | +23.0% | -20.4% |
| Return, 1 year | +35.5% | +5.7% |
| P/E (TTM) | – | – |
| P/B | 200.0 | 6.7 |
| P/E percentile vs own 5y | 15th | 40th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +36.2% | – |
| Net profit growth (YoY) | -303.6% | -39.6% |
| Gross margin | 98.8% | – |
| Operating margin | -3.1% | – |
| Net margin | -18.7% | – |
| Return on equity | -252.7% | -21.2% |
| Analyst target vs. price | +56.2% | +81.9% |
| Analyst buy share | 91% | 100% |
| RSI (14) | 35 | 32 |
| 30-day volatility | 45.1% | 74.4% |
| Max drawdown, 1 year | -33.5% | -34.2% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BLTE is the largest of the group by market value.
- TVTX has returned the most over the past year.
- TVTX has been the calmest stock over the last 30 days.